{"filing":{"accession_number":"0001104659-26-075127","cik":"0000872589","ticker":"REGN","company_name":"REGENERON PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"tm2618117d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926075127/tm2618117d1_8k.htm"},"events":[{"id":11541,"run_id":10137,"accession_number":"0001104659-26-075127","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 filing discloses the results of Regeneron's 2026 Annual Meeting of Shareholders held on June 12, 2026, including voting outcomes for three proposals: election of Class II directors (five nominees), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.","company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8147,"accession_number":"0001104659-26-075127","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of Regeneron's 2026 Annual Meeting of Shareholders held on June 12, 2026, including voting outcomes for three proposals: election of Class II directors (five nominees), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:08:54.669662+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8147,"accession_number":"0001104659-26-075127","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of Regeneron's 2026 Annual Meeting of Shareholders held on June 12, 2026, including voting outcomes for three proposals: election of Class II directors (five nominees), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:08:54.669662+00:00","company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","filing_date":"2026-06-17"}]}